Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Intravenous mecillinam compared with other β-lactams as targeted treatment for Escherichia coli or Klebsiella spp. bacteraemia with urinary tract focus

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. ResFinder 4.0 for predictions of phenotypes from genotypes

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Association between vancomycin-resistant Enterococcus faecium colonization and subsequent infection: a retrospective WGS study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Bacterial and fungal bloodstream infections in pediatric liver and kidney transplant recipients

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Presence of streptococci and frequent tonsillitis among adolescents with psoriasis

    Research output: Contribution to journalLetterpeer-review

View graph of relations

Background: Mecillinam (amdinocillin) is active against Gram-negative bacteria. Clinical data on the efficacy of IV mecillinam for severe urinary tract infections is sparse. Objectives: To assess the effectiveness of targeted IV mecillinam compared with other b-lactams for bacteraemia with Escherichia coli and Klebsiella spp. and a urinary tract focus. Patients and methods: We performed a retrospective cohort study at five university hospitals in the Capital Region of Denmark from 1 January 2012 to 31 December 2017. We used Cox proportional hazard regression to compare the primary composite endpoint (all-cause mortality or bacteraemia recurrence within 30 days) between patients treated with mecillinam versus ampicillin, cefuroxime, piperacillin/tazobactam and meropenem. Results: We included 1129 patients in the primary analysis, of which 146 were given IV mecillinam as targeted treatment. We found no significant difference in the primary endpoint between patients treated with mecillinam versus ampicillin and cefuroxime, but found a higher risk for the primary endpoint in the piperacillin/tazobactam and meropenem groups, with adjusted HRs of 2.22 (95% CI 1.24-3.97, P < 0.01) and 2.48 (95% CI 1.04-5.93, P = 0.04), respectively, compared with mecillinam. Conclusions: The results of this study suggest that IV mecillinam may be a suitable targeted treatment for bacteraemia with a urinary tract focus. However, these results need confirmation by randomized controlled studies.

Original languageEnglish
JournalThe Journal of antimicrobial chemotherapy
Volume76
Issue number1
Pages (from-to)206-211
Number of pages6
ISSN0305-7453
DOIs
Publication statusPublished - 1 Jan 2021

ID: 60942688